Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05482074

Recruitment Status : Withdrawn (Principal Investigator left the institute)

First Posted : August 1, 2022

Last Update Posted : January 19, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

AstraZeneca

Information provided by (Responsible Party):

Dana-Farber Cancer Institute

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Withdrawn
Estimated Primary Completion Date :	May 1, 2026
Estimated Study Completion Date :	May 1, 2027

To Top